Drug Profile
GSK 2636771
Alternative Names: GSK2636771Latest Information Update: 12 Jul 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Yonsei University Health System
- Class Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Imidazoles; Morpholines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Gastric cancer
- Discontinued Malignant melanoma; Prostate cancer; Solid tumours
Most Recent Events
- 03 Jun 2022 Efficacy and safety data from a phase I/II trial in Prostate cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 16 Sep 2021 Efficacy and safety data from a phase I/II trial in Solid tumours presented at the 46th European Society for Medical Oncology Congress
- 23 Jun 2020 National Cancer Institute completes enrolment in the phase II MATCH-Subprotocol N trial for Cancer (Late-stage disease) in USA (PO) (NCT04439149)